Study confirms heart failure risks in Actos, Avandia

09/27/2007 | MSNBC

The latest in a series of studies on diabetes drugs Actos and Avandia has confirmed the treatments' link to an increased risk of heart failure, notably in patients with a history of heart disease and congestive cardiac failure. Takeda Pharmaceutical Co.'s Actos and GlaxoSmithKline's Avandia, however, did not appear to increase the risk of cardiac-related death, according to the study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care